BioStem Technologies, Inc. (BSEM)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 3 | 4 | 7 | 17 | 302 | 47 | -60 | 29 |
| Operating profit | $m | -1 | -23 | ||||||
| Net profit | $m | -2 | -1 | -7 | -8 | 32 | -7 | -28 | -32 |
| EPS reported | $ | -0.39 | -1.68 | ||||||
| Operating cashflow per share | $ | 0.59 | -0.34 | ||||||
| Capex per share | $ | 0.20 | 0.17 | ||||||
| FCF per share | $ | 0.39 | -0.51 | ||||||
| Free cash flow | $m | 7 | -9 | ||||||
| Net debt | $m | -26 | -6 | ||||||
| Book value equity | $m | 39 | 28 | ||||||
| Book value per share | $ | 2.34 | 1.59 | ||||||
| Number of shares | m | 16.73 | 17.33 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 1.63 | 2.31 | ||||||
| P/S LTM | x | 1.34 | -1.06 | ||||||
| P/FCF LTM | x | 9.67 | -7.22 | ||||||
| EV/EBITDA LTM | x | -79.87 | -1.71 | ||||||
| EV/Sales LTM | x | 0.79 | -0.95 | ||||||
| Earnings Yield LTM | % | -10.33% | -44.01% | ||||||
| FCF Yield | % | +10.34% | -13.86% | ||||||
| Quality | |||||||||
| ROE | % | -16.81% | -76.13% | ||||||
| ROIC | % | -1.62% | -80.92% | ||||||
| Operating margin | % | -1.45% | +38.70% | ||||||
| Gross margin | % | +93.13% | +1.14% | ||||||
| FCF/Sales | % | +13.88% | +14.64% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -84.27% | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | -72.60% | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 1.98 | -7.22 | ||||||
| Net Debt/EBITDA | x | 55.82 | 0.26 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | +5.06% | +1.94% | ||||||
| Net debt/Equity | x | -0.67 | -0.22 | ||||||
| Gross debt/equity | x | 0.09 | 0.04 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
BioStem Technologies, Inc. (BSEM)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free